Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Harvard Business School
Daiichi Sankyo
Queensland Health
McKesson
Fish and Richardson
Federal Trade Commission
Julphar

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,551,992

« Back to Dashboard

Summary for Patent: 6,551,992
Title: Stable insulin formulations
Abstract:The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Inventor(s): DeFelippis; Michael Rosario (Indianapolis, IN), Dobbins; Michael Allen (Lebanon, IN), Frank; Bruce Hill (Indianapolis, IN), Li; Shun (Indianapolis, IN), Rebhun; Dawn Marie (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/450,794
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 6,551,992

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,551,992

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,034,054 Stable insulin formulations ➤ Try a Free Trial
6,906,028 Stable insulin formulations ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,551,992

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1283051 ➤ Try a Free Trial
Portugal 884053 ➤ Try a Free Trial
Poland 194244 ➤ Try a Free Trial
Poland 337324 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Medtronic
Farmers Insurance
Argus Health
Colorcon
Teva
Mallinckrodt
Harvard Business School
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.